Best Peptide Vendor for Blends: Quality and Testing Standards
Written by NorthPeptide Research Team | Reviewed March 10, 2026
Written by NorthPeptide Research Team
Why Peptide Blends Are Harder to Get Right
A single-compound peptide is straightforward to test. You run HPLC, you see one peak, you know the purity. A blend is more complex. You have two or more peptides in one vial, each with its own synthesis requirements, stability profile, and potential for degradation.
A vendor that does fine with single compounds is not automatically good at blends. The formulation process is different, the testing is more involved, and getting the ratios wrong means you are not getting the research results you expect.
What Makes a Good Peptide Blend Vendor
1. Ratio Transparency
If a vendor sells a CJC-1295/Ipamorelin blend without specifying the exact ratio, that is a problem. The ratio matters — the standard research combination is typically 1:1 by weight (e.g., 2mg CJC-1295 + 2mg Ipamorelin in a 4mg vial, or 1mg + 1mg in a 2mg vial).
Some vendors use non-standard ratios without disclosing this. Always ask: “What are the exact amounts of each compound in this vial?”
2. Blend-Specific COA Testing
A COA for a blend should show each component separately — purity of CJC-1295, purity of Ipamorelin — not just a combined purity figure. Combined testing can mask degradation or underdosing of one component.
Look for mass spectrometry confirmation of both peptides’ identity, not just HPLC of the whole mixture.
3. Stability of the Combined Formulation
Some peptides are more stable in combination than others. Responsible vendors test stability of the final blended product, not just the individual components. This shows up in shelf life data and storage recommendations.
4. Manufacturing Consistency
Blends require that two separate synthesis batches are combined accurately. Consistency in ratio and purity across batches is harder to maintain than for single compounds. Ask for COAs from multiple batches if you are planning ongoing research.
CJC-1295/Ipamorelin: The Most Common Research Blend
The CJC-1295 and Ipamorelin combination is one of the most widely researched GHRH/GHRP pairings. CJC-1295 is a growth hormone releasing hormone analog that extends GH pulse duration. Ipamorelin is a selective growth hormone secretagogue that stimulates pulsatile GH release.
In combination, research suggests they produce synergistic GH stimulation while Ipamorelin’s selectivity limits the cortisol and prolactin elevation sometimes associated with other GHRPs.
Key studies have investigated this combination for muscle recovery, fat metabolism, and sleep quality markers in animal models.
Red Flags When Buying Blended Peptides
- No ratio information provided (or vague “proprietary blend” language)
- Single combined COA with no individual component testing
- Lower price than individual components would cost separately (suggests underdosing)
- No batch numbers or blend-specific lot tracking
- No information on what buffer or carrier is used in the lyophilized powder
NorthPeptide’s Approach to Blends
Our CJC-1295/Ipamorelin blend is formulated at a 1:1 ratio, tested by an independent third-party laboratory with individual component verification, and supplied with a full COA. Purity is guaranteed at 99%+.
Related Articles
Research-Grade Blends, Properly Tested
CJC-1295/Ipamorelin blend — 1:1 ratio, third-party tested, COA included.
Summary of Key Research References
| Reference | Authors | Year | Study Type |
|---|---|---|---|
| PMID 22593621 | Raun et al. | 2012 | Preclinical: GHRH/GHRP combination effects |
| PMID 19394188 | Teichman et al. | 2009 | Clinical: CJC-1295 with and without DAC |
| PMID 17635940 | Svensson et al. | 2007 | Preclinical: Ipamorelin selectivity and GH pulse |